These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 22583734)

  • 21. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Myerson JS; Iqbal SA; O'Brien ME; Popat S
    Clin Lung Cancer; 2010 Sep; 11(5):E5-8. PubMed ID: 20837451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib.
    Bulj TK; Krunic AL; Cetner AS; Villano JL
    Br J Dermatol; 2010 Sep; 163(3):633-7. PubMed ID: 20222923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
    Olawaiye A; Lee LM; Krasner C; Horowitz N
    Gynecol Oncol; 2007 Sep; 106(3):628-30. PubMed ID: 17561233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted kinase inhibitors in lung cancer: from EGFR to patients.
    Apolone G; La Vecchia C; Garattini S
    Eur J Cancer; 2006 Jan; 42(2):124-5. PubMed ID: 16324837
    [No Abstract]   [Full Text] [Related]  

  • 26. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
    Garfield DH
    J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
    Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
    Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
    J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma.
    Hayashi M; Sekikawa A; Saijo A; Takada W; Yamawaki I; Ohkawa S
    Anticancer Res; 2005; 25(3c):2435-8. PubMed ID: 16080471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
    Taguchi F; Solomon B; Gregorc V; Roder H; Gray R; Kasahara K; Nishio M; Brahmer J; Spreafico A; Ludovini V; Massion PP; Dziadziuszko R; Schiller J; Grigorieva J; Tsypin M; Hunsucker SW; Caprioli R; Duncan MW; Hirsch FR; Bunn PA; Carbone DP
    J Natl Cancer Inst; 2007 Jun; 99(11):838-46. PubMed ID: 17551144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 35. Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib.
    Ammannagari N; Ahmed S; Patel A; Bravin EN
    QJM; 2013 Sep; 106(9):869-70. PubMed ID: 23596263
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pancreatic carcinoma].
    Okamoto T; Onda S
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():463-7. PubMed ID: 23513884
    [No Abstract]   [Full Text] [Related]  

  • 37. Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.
    Madan V; Ortiz-López LI; Sakunchotpanit G; Chen R; Nayudu K; Nambudiri VE
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1755-1766. PubMed ID: 38907875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara
    Le A; Azouz A; Thomas S; Istaces N; Nguyen M; Goriely S
    Front Immunol; 2020; 11():604785. PubMed ID: 33613525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
    Vastarella M; Fabbrocini G; Sibaud V
    Drug Saf; 2020 May; 43(5):395-408. PubMed ID: 31981081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances on the roles of epidermal growth factor receptor in psoriasis.
    Wang S; Zhang Z; Peng H; Zeng K
    Am J Transl Res; 2019; 11(2):520-528. PubMed ID: 30899359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.